FDA to increase drug competition and speed up ANDA reviews

The US Food and Drug Administration (FDA) has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

FDA issues new guidance to boost generic competition

3 October 2017 The US Food and Drug Administration has issued new guidance as part of its bid to target the barriers to generic drug competition.

Americas

FDA’s Gottlieb launches biosimilars action plan

19 July 2018 The US Food and Drug Administration is not going to play regulatory ‘whack-a-mole’ with companies trying to delay or derail the entry of biosimilar competitors, according to Scott Gottlieb, commissioner of the FDA.

Americas

FDA issues latest guidance to stop ‘gaming’ of system

3 October 2018 Scott Gottlieb, commissioner of the Food and Drug Administration,, yesterday announced another set of guidelines aimed at facilitating the entry of generic drugs to the market and preventing “gaming” of the approval system.